Drug
Apomorphine clinical trials
Also written APL-130277, KW-6500, Apokinon and APOKYN.
- studies test it
- 38
- open now
- 2
- in phase 3
- 15
- first study started
- 1999
Keep track of what changes. Save the Apomorphine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
38 studies that test it; most in 2017 (5)
| Year | Studies |
|---|---|
| 1999 | 2 |
| 2001 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 4 |
| 2009 | 3 |
| 2010 | 3 |
| 2012 | 2 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 2
- 16
- Phase 3
- 15
- Phase 4
- 6
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 19
Sumitomo Pharma America, Inc. (6) · Kyowa Kirin Co., Ltd. (4) · Mylan Bertek Pharmaceuticals (4) · MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals (3) · Rennes University Hospital (3) · Rambam Health Care Campus (2) · South Glasgow University Hospitals NHS Trust (2) · University of Liege (2)
Often tested with
Tested in the same studies.
Dopamine Agonists (1) · Levodopa (1) · Hydrocortisone (1)
Studies
Open first, then newest update. How each study uses Apomorphine is read from its arms, and is right about nine times in ten.
Testing it · 38
- Motor Network PhysiologyRecruitingNot applicableUniversity of Texas Southwestern Medical CenterNCT04957095Written as Apomorphine Injectable Solution
- Apomorphine in Severe Brain-injured PatientsRecruitingPhase 2/3University of LiegeNCT05213169Written as Apomorphine Hydrochloride 5mg/ml
- Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)CompletedPhase 3Rennes University HospitalNCT02864004Written as Apomorphine
- Infusion of Apomorphine: Long-term Safety StudyActive, not recruitingPhase 3MDD US Operations, LLC a subsidiary of Supernus PharmaceuticalsNCT02339064Written as apomorphine infusion
- Monocentric, Prospective Study to Assess the Pharmacokinetic Profile of Continuous and Diurnal Subcutaneous Apomorphine Infusion in Patients With Parkinson's DiseaseCompletedPhase 4Rennes University HospitalNCT04887467Written as Apomorphine
- Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's DiseaseCompletedPhase 4Clinique Beau SoleilNCT02940912Written as Apomorphine
- Treatment of Apomorphine-induced Skin Reactions: a Pilot StudyTerminatedPhase 2University Medical Center GroningenNCT02230930Written as Apomorphine 0.25% (2.5mg/ml)
- Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French HospitalsCompletedNot applicableRennes University HospitalNCT03693872Written as Apomorphine
- Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's DiseaseCompletedPhase 3Sumitomo Pharma America, Inc.NCT02542696Written as APL-130277
- Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®TerminatedPhase 4MDD US Operations, LLC a subsidiary of Supernus PharmaceuticalsNCT02549573Written as APOKYN
- Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)CompletedPhase 4MDD US Operations, LLC a subsidiary of Supernus PharmaceuticalsNCT01770145Written as APOKYN
- A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)CompletedPhase 3Sumitomo Pharma America, Inc.NCT03391882Written as APL-130277
- Apomorphine Effects on Pain in Parkinson's DiseaseStatus unknownPhase 2/3University of CalgaryNCT04879134Written as Apomorphine Injectable Solution
- Treating Severe Brain-injured Patients With ApomorphineStatus unknownPhase 2University of LiegeNCT03623828Written as Apomorphine Hydrochloride 50Mg/10mL Prefilled Syringe
- Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa TherapyCompletedPhase 2Kyowa Kirin Co., Ltd.NCT00610103Written as apomorphine hydrochloride
- A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" EpisodesCompletedPhase 2Sumitomo Pharma America, Inc.NCT03292016Written as APL-130277
- A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" EpisodesCompletedPhase 2Sumitomo Pharma America, Inc.NCT03187301Written as APL-130277
- Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's DiseaseCompletedPhase 3Sumitomo Pharma America, Inc.NCT02469090Written as APL-130277
- A Study to Examine APL-130277 in Patients With Parkinson's DiseaseCompletedPhase 2Sumitomo Pharma America, Inc.NCT02228590Written as APL-130277
- Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's DiseaseCompletedPhase 3Britannia Pharmaceuticals Ltd.NCT02006121Written as Apomorphine hydrochloride
Codes
What other systems call Apomorphine · ClinicalTrials.gg INT007016
- MeSH (NLM) D001058ApomorphineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) N21FAR7B4SAPOMORPHINEConfirmed FDA, NLM, Wikidata
- RxNorm 1043Confirmed FDA, Wikidata
- Wikidata Q269111apomorphineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61639ApomorphineOne source FDA
- DrugBank DB00714One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D001058 | Apomorphine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | N21FAR7B4S | APOMORPHINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1043 | — | Confirmed FDA, Wikidata |
| Wikidata | Q269111 | apomorphine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61639 | Apomorphine | One source FDA |
| DrugBank | DB00714 | — | One source Wikidata |
Also registered as apomorphine hydrochloride (UNII F39049Y068 · RxNorm 71225) and apomorphine hydrochloride anhydrous (UNII 9K13MD7A0D).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.